Trapping female mosquitoes using an Autocidal Gravid Ovitrap (AGO trap) could be the best way to prevent chikungunya virus infection, reports a new study. The findings of the study are published in the journal PLOS Neglected Tropical Diseases.
The U.S. Centers for Disease Control and Prevention (CDC) recently developed an Autocidal Gravid Ovitrap that attracts and captures female mosquitos looking for a site to lay eggs. Now, researchers report that AGO traps successfully protected people from infection with chikungunya virus (CHIKV) in communities in Puerto Rico.
The lack of effective tools to control Aedes aegypti mosquito populations has resulted in the continued expansion of dengue virus, Zika virus, and CHIKV. Some recent attempts at curbing mosquito populations have resulted in reductions in mosquito density but not reductions in human disease. AGO traps consist of a pail with hay and water to attract egg-bearing female mosquitoes and a sticky lining to which the insects adhere. Previous studies have shown that placing three AGO traps outside of 85% of homes in a community resulted in an 80% reduction in adult mosquito populations, but the studies did not assess rates of mosquito-borne diseases in humans.
A total of 114 participants (34.9%) were seropositive for CHIKV. Among people who spent most of their daytime hours inside the community they lived in, 10.3% were seropositive for CHIKV in communities with AGO traps, whereas 48.7% were positive for CHIKV in communities without traps. Among all participants, including those who did not spend as much daylight time within the community, 26.1% were seropositive for CHIKV in the intervention communities, and 43.8% were positive in communities without traps.
"AGO traps are a novel chemical-free, effective approach to control Ae. aegypti populations and provide protection from infection with the pathogens that these mosquitos transmit," the researchers say. "Further evaluations should determine if AGO traps are sustainable and effective in larger-scale community trials."